Skip to content

Sulindac

    Generic Only

    DEA Class;  Rx

    Common Brand Names; Clinoril, Sulin

     NSAIDs

    Acetic acid NSAID; has analgesic and antipyretic properties; reported efficacy in the regression of colorectal polyps associated with familial adenomatous polyposis; causes an increased risk of serious gastrointestinal adverse effects; may cause an increased risk of serious cardiovascular events; use lowest effective dose for the shortest possible duration.

    For the treatment of acute subacromial bursitis, supraspinatus tendinitis, and acute gouty arthritis.
    For the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and moderate pain including bone pain, arthralgia, and myalgia.
    Oral dosage
    For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).
    Oral dosage
    For the post-surgery treatment of colorectal polyps related to familial adenomatous polyposis (FAP).

    Hypersensitivity to drug or excipients

    In the setting of CABG surgery

    History of asthma, urticaria, or any other type of reaction after taking aspirin or other NSAIDs

    1-10%

    GI pain (10%)

    Constipation (3-9%)

    Diarrhea (3-9%)

    Dizziness (3-9%)

    Dyspepsia (3-9%)

    Headache (3-9%)

    Nausea (3-9%)

    Rash (3-9%)

    Abdominal cramps (1-3%)

    Anorexia (1-3%)

    Edema (1-3%)

    Nervousness (1-3%)

    Pruritus (1-3%)

    Tinnitus (1-3%)

    Vomiting (1-3%)

    <1%

    Hypersensitivity reactions (including anaphylaxis, angioedema, bronchospasm, dyspnea) Sulindac therapy should be discontinued & not reinstituted if unexplained fever or other evidence of hypersensitivity occurs

    Thrombocytopenia

    Ecchymosis

    Purpura

    Leukopenia

    Agranulocytosis

    Neutropenia

    Bone marrow depression

    Sulindac metabolites have been reported rarely as the major or a minor component in renal stones in association with other calculus components; the drug should be used with caution in patients with a history of renal lithiasis, and they should be kept well hydrated while receiving therapy

    Pancreatitis has been reported in patients receiving therapy; should pancreatitis be suspected, the drug should be discontinued and not restarted, supportive medical therapy instituted, and patient monitored closely with appropriate laboratory studies (eg, serum and urine amylase, amylase/creatinine clearance ratio, electrolytes, serum calcium, glucose, lipase, etc.); a search for other causes of pancreatitis as well as those conditions which mimic pancreatitis should be conducted

    Because of reports of adverse eye findings with non-steroidal anti-inflammatory agents, it is recommended that patients who develop eye complaints during treatment have ophthalmologic studies

    In patients with poor liver function, delayed, elevated and prolonged circulating levels of the sulfide and sulfone metabolites may occur; such patients should be monitored closely; a reduction of daily dosage may be required

    Pregnancy Category: B; D if used for prolonged periods, or near term (may cause premature closure of ductus arteriosus)

    Lactation: not known if distributed in milk

    Adults

    400 mg/day PO.

    Elderly

    400 mg/day PO.

    Adolescents

    6 mg/kg/day PO or 400 mg/day PO, whichever is less, has been suggested. However, data are limited.

    Children

    6 mg/kg/day PO or 400 mg/day PO, whichever is less, has been suggested. However, data are limited.

    Tablet

    • 150mg
    • 200mg